Companies › Hansa Biopharma
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Genitourinary, Other; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Imlifidase IgG-degrading enzyme that cleaves IgG into F(ab')2 and Fc fragments, neutralizing Fc-media | IGHG1 | Phase 3 | Long Term Efficacy and Safety; Kidney Transplantation in Highly Sensitized Patients | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05753930 | Imlifidase | Phase 2 | Kidney Transplantation in Highly Sensitized Patients | Genitourinary | Feb 2027 |
| NCT05937750 | Imlifidase | Phase 3 | Long Term Efficacy and Safety | Other | Apr 2030 |
–
Endo USA Inc., a Keenova Therapeutics Company Heron Therapeutics CUTISS Genexine Gameto
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.